Sales & Marketing News | pharmaphorum

News

Organon makes dermatology play with $1.2bn Dermavant buyout

Organon is paying $175 million upfront to buy Roivant's dermatology unit Dermavant and its topical psoriasis therapy Vtama, which is also under review by the FDA for atopic dermatitis.

News

PBM strikes back at FTC over drug pricing report

A pharmacy benefit manager has thrown a legal punch at the Federal Trade Commission (FTC), taking issue with the agency's recent report accusing PBMs of using anti-competitive practices to

News

Noom offers cut-price compounded GLP-1 drug for obesity

Digital health company Noom has launched a compound pharmacy-made version of Novo Nordisk's obesity drug semaglutide to make the drug more accessible to consumers in the US.

News

Lilly on alert as new Kisqali approval threatens Verzenio

Novartis' CDK4/6 inhibitor Kisqali has claimed a broad FDA approval in early breast cancer that could give it an edge over class rival Verzenio from Eli Lilly.

News

Tobacco firm PMI divests Vectura at a loss after backlash

Philip Morris International (PMI) is selling inhaled drug specialist Vectura to Molex Asia Holdings for a fraction of the £1.1 billion ($1.45 billion) it paid for the business three years a

News

Trial sets up filings for Boehringer IPF drug nerandomilast

With new phase 3 data in hand, Boehringer Ingelheim is preparing to file for approval of nerandomilast, a would-be successor to its blockbuster idiopathic pulmonary fibrosis (IPF) therapy O

Organon makes dermatology play with $1.2bn Dermavant buyout

PBM strikes back at FTC over drug pricing report

Noom offers cut-price compounded GLP-1 drug for obesity

Lilly on alert as new Kisqali approval threatens Verzenio

Tobacco firm PMI divests Vectura at a loss after backlash

Trial sets up filings for Boehringer IPF drug nerandomilast

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

News

Editor's Picks